Global Hepatitis C Drugs Market (2019 to 2025) - By Drugs, Distribution Channels, Regions & Company Analysis - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Hepatitis C Drugs Market Global Forecast By Drugs, Distribution Channels, Regions, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Hepatitis C is a viral infection that causes severe damage to the human body; it is an infection caused by a virus that damages the liver, which leads to inflammation. It spread through contaminated blood. The prevalence of hepatitis C infection among the global populace is escalating. This is mainly caused by sharing needles, unsterilized medical equipment, and a blood transfusion from infected mothers to newborn babies. As per the research analysis, the Global Hepatitis C Drugs Market would be US$ 5.9 Billion by 2025.

In recent years, several drugs have been launched due to the high prevalence of Hepatitis C across the globe. The newly launched drug by AbbiVie i.e., Mavyret, has led to a downfall in the revenue of one of the market leader i.e. Gilead's. Mavyret has several advantages compared to other drugs such as its treatment course is shorter, and it is much cheaper. Harvoni drugs are popular in India, and it's easier affordable among the public.

Oral injections and dosages are required weekly in Hepatitis C; at the same time, its side effects can lead to permanent damage of other organs of patients. Around the globe, many clinical trials, as well as numerous successful drug clearances, give traction to this market. Apart from that, the rising number of regulatory approvals will further boost the market during the forecast time frame.

Hepatitis C drugs have witnessed numerous drug approvals likewise, in the year 2019, USFDA approves Mavyret for the treatment of pediatric hepatitis patients. For the treatment of all genotypes of Hepatitis C, Mavyret was the first treatment.

In the North American region, rising adoption of hepatitis C drugs will favor the surging of the market. The market share of Asia - Pacific's and Latin American regions will grow during the forecast period.

The report titled Hepatitis C Drugs Market Global Forecast by Drugs (Mavyret, Viekira Pak, Harvoni, Epclusa, Sovaldi, Vosevi, Zepatier, Others), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacy), Regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Company Analysis (Abbvie, Gilead Sciences, Merck, Bristol-Myers Squibb, Others) provides a complete analysis Hepatitis C market globally.

Key Topics Covered:

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamic

4.1 Growth Driver

4.2 Challenges

5. Global Hepatitis C Drugs Market

6. Market Share Analysis - Global Hepatitis C Drugs

6.1 Regions

6.2 Drugs

6.3 Distribution Channels

6.4 Company

7. Regions - Global Hepatitis C Drugs Market

7.1 North America

7.2 Europe

7.3 Asia Pacific

7.4 Latin America

7.5 Middle East & Africa

8. Drugs - Global Hepatitis C Drugs Market

8.1 Mavyret

8.2 Viekira Pak

8.3 Harvoni

8.4 Epclusa

8.5 Sovaldi

8.6 Vosevi

8.7 Zepatier

8.8 Others

9. Distribution Channels - Global Hepatitis C Drugs Market

9.1 Hospital Pharmacies

9.2 Retail Pharmacies

9.3 Online Pharmacy

10. Merger and Acquisitions

11. Company Analysis - Global Hepatitis C Drugs Market

11.1 Abbvie

11.2 Gilead Sciences, Inc.

11.3 Merck & Co. Inc.

11.4 Bristol-Myers Squibb

11.5 Others

For more information about this report visit https://www.researchandmarkets.com/r/lif6mj